News|Articles|December 27, 2024

2024’s Top DTC Stories

Author(s)Mike Hollan

New technologies are creating more efficient ways for pharma companies to work directly with consumers.

Pharm Exec Exclusive: Mark Cuban Talks Drug Pricing

Now more than two years into launching his alternative and transparent drug payment model, the longtime entrepreneur, in an interview with Pharm Exec, discusses the prescription drug cost landscape and shares his recipe for true disruption to the pharma pricing machine.

The Impact of Eli Lilly's New DTC Platform on Rx Drug Sales and Patient Access: An Interview with Bill Roth, General Manager, Managing Partner, Blue Fin Group

In an interview with Nicholas Saraceno, Bill Roth, General Manager, Managing Partner, Blue Fin Group, discusses changes that will come with the pharma giant's new platform.

Not Just Another Tactic: Why Pharmaceutical Brands Need to Build a Strategy Around Point of Care Messaging

Point of care messaging offers unique advantages in pharmaceutical marketing and should be a high priority in brand strategy discussions.

Transforming Patient Care Management: Q&A with Dea Belazi

The AscellaHealth CEO discusses how new technologies are increasing the options in patient care.

Telehealth & Its Role in Providing Access to Weight Loss Drugs

In this part of their Pharmaceutical Executive video interview, UpScriptHealth's Peter Ax, Founder and CEO, and George Jones, Chief Operations Officer, share their predictions for the future of telehealth and its role in providing access to essential medications like weight loss drugs.

Related to this article

Pharmaceutical Executive Daily
FDA approves Ultragenyx's Fayuvi as the first treatment for Sanfilippo syndrome type A, Lisata Therapeutics acquires Marea Therapeutics as mAbxience partners with Sandoz on a hemophilia A biosimilar, and Joe Cunningham argues that executive drug-pricing deals alone won't fix costs.
Former U.S. Representative Joe Cunningham (D-SC), spokesperson, Pharmaceutical Reform Alliance.
Former U.S. Representative Joe Cunningham (D-SC), spokesperson, Pharmaceutical Reform Alliance. dismisses the pharmaceutical industry's innovation argument against MFN pricing.